Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term follow-up of AAV2-REP1 and AAV8-RPGR retinal gene therapy in choroideremia and X-linked retinitis pigmentosa
2023-507994-16-00Phase 3Completed
- Sponsor
- Biogen
- Start
- Oct 2024
- Modality
- Gene Therapies
- Countries
- 6
01
Overview
Phase 3, open-label trial of timrepigene emparvovec in choroideremia and X-linked retinitis pigmentosa (XLRP) (2 cohorts), sponsored by Biogen. Primary endpoint: Safety assessments. Started Oct 2024; status: completed.
02
Drugs
timrepigene emparvovec
03
Conditions
choroideremiaX-linked retinitis pigmentosa (XLRP)
Beyond the preview
Go deeper on 2023-507994-16-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507994-16-00.